Table 2:
MIDAN | Glomeruli, n | Global sclerosis, n (%) | Segmental sclerosis | Tubulointerstitial fibrosis, n | AH, n | GSEC | PH | Swollen mitochondria |
---|---|---|---|---|---|---|---|---|
TIN | 12 | 0 (0) | − | 3 | 1 | − | − | + |
TIN | 11 | 5 (37) | − | 3 | 0 | − | − | N/A |
TIN | 5 | 3 (60) | − | 3 | 0 | − | − | N/A |
TIN | 15 | 9 (60) | − | 3 | 2 | − | − | N/A |
GD | 10 | 10 (1) | + | 0 | 0 | − | + | N/A |
GD | 14 | 5 (36) | + | 2 | 3 | − | − | N/A |
GD | 2 | 1 (50) | + | 3 | 0 | − | − | N/A |
AH: arteriolar hyaline thickening; GD: glomerular disease; GSEC: granular swollen epithelial cells; N/A/: not available; PH: podocyte hypertrophy; TIN: tubulointerstitial nephropathy; −: negative; + positive. Grading of severity for tubulointerstitial fibrosis and arteriolar hyaline thickening followed the 2017 Banff Lesion Score [30].